KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensGrof gekalibreerdHuidige impliciete kansbefore April 2027 67%Koploper van 6 uitkomsten
Marktkwaliteit
39 / 100
Lage kwaliteit24u volume
€ 0
Liquiditeit
€ 2K
Lage liquiditeitBied / Laat
3.0% / 9.0%
Spread
6.0 pt
Brede spreadMarktdata
Bijgewerkt 14 minuten geleden
24 mrt 26, 14:001 sep 26, 14:00
Trends
0%
Alleen virtueel geld, geen echt geldGeen financieel advies
Gekozen uitkomst
before September10%
Volumetrend
$124 jul13d aan data25 jul
Gerelateerde Markten
Testosterone unscheduled/rescheduled more permissively in US by end of 2028?
€ 511,2Ja: 17.8%MANIFOLD MARKETS
MANIFOLD MARKETS2026 Ebola epidemic deaths?
€ 500,1<250: 0.2%MANIFOLD MARKETS
MANIFOLD MARKETSWill there be a cure for schizophrenia before 2032?
€ 439,4Ja: 11.8%MANIFOLD MARKETS
MANIFOLD MARKETS
When will Intellia Therapeutics submit a BLA for Lonvo-z?
€ 5before November: 69%KALSHI
KALSHI
Will there be a year without polio before 2030?
€ 0Ja: 11%KALSHI
KALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?
€ 0before September: 15%KALSHI
KALSHIActief in deze onderwerpen
Gerelateerd Nieuws
Crypto is the canary in the coal mine for the quantum computing threat, experts sayCoindesk
Galaxy Digital opens $5M fund for Bitcoin quantum security researchCrypto News
Claude's Fable 5 just solved an 87-year-old math problem, and it matters for bitcoinCoindesk
Google DeepMind, Isomorphic Labs Unveil AI-Powered Bioresilience PlanBlockchain.News
NVIDIA's Ising Decoder Slashes Color Code Errors 300xBlockchain.News
NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.NewsRegels
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.